NebraskaChildren Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Children are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Population Estimate Benchmark Distance to Benchmark
Children ages 19-35 months who received 4 or more doses of diphtheria-tetanus-pertussis vaccine Total 89.4 90.6 1.3%
Children ages 19-35 months who received 3 or more doses of hepatitis B vaccine Total 94.0 96.4 2.4%
Children ages 19-35 months who received 1 or more doses of measles-mumps-rubella vaccine Total 93.7 96.4 2.8%
Children ages 19-35 months who received 3 or more doses of polio vaccine Total 94.0 97.3 3.4%
Children ages 19-35 months who received 1 or more doses of varicella vaccine Total 91.2 95.7 4.7%
Adolescents ages 13-15 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years Total 89.1 95.2 6.4%
Measures That Are Close to Benchmark
Measure Population Estimate Benchmark Distance to Benchmark
Adolescents ages 16-17 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years Total 83.3 95.9 13.2%
Adolescents ages 13-15 who received 1 or more doses of meningococcal conjugate vaccine Total 81.1 95.4 15.0%
Adolescents ages 16-17 who received 1 or more doses of meningococcal conjugate vaccine Total 78.9 96.2 17.9%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Population Estimate Benchmark Distance to Benchmark
Children ages 19-35 months who received full series Haemophilus influenzae type B Total 87.2
Children ages 19-35 months who received 4 or more doses of pneumococcal conjugate vaccine Total 88.1
Composite measure: Children ages 19-35 months who received all recommended vaccines Total 80.6
Adolescent aged 13-15 years who received 3 or more doses of human papillomavirus (HPV) vaccine Total 38.0
Adolescents ages 13-15 years (excluding adolescents who have had varicella) vaccinated with at least 2 doses of varicella Total 90.1
Children aged 2 years treated at a HRSA supported health center who received age appropriate vaccines. Total 60.3
Children ages 3-17 treated at a HRSA supported health centers who received weight screening and follow-up Total 84.0